|
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
NCT ID : 03345095
Phase : 3
|
Kesari
|
|
Pemetrexed for the Treatment of Chordoma
NCT ID : 03955042
Phase : 1
|
Kesari
|
|
StimRouter™ for Pain Management in Post-stroke Shoulder Pain (PSSP)
NCT ID : 03093935
Protocol Number : STMR – PAIN 002 PSSP
|
Langevin
|
|
Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
NCT ID : 03709888
Protocol Number : JWCI-17-0101
|
Kesari
|
|
Allogeneic Human Mesenchymal Stem Cells for Alzheimer’s Disease
NCT ID : 02833792
Protocol Number : STEM105-M-AD
Phase : 2
|
Kesari
|
|
Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial
NCT ID : 02873312
Protocol Number : CP-STMR-OAB-002
|
Langevin
|
|
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT ID : 02847559
Protocol Number : NU 16C02
Phase : 11
|
Kesari
|
|
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
NCT ID : 03425292
Protocol Number : JWCI-17-0801
|
Kesari
|
|
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR)
NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : 3
|
Kesari
|
|
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
NCT ID : 03637764
Protocol Number : ACT15377
Phase : 1 and 2
|
Kesari
|
|
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I
|
Kesari
|
|
Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II
|
Kesari
|
|
A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)
NCT ID : 03131960
Protocol Number : MT-St-03
Phase : 3
|
Langevin
|
|
A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03463265
Protocol Number : GBM-007
Phase : 2
|
Kesari
|
|
A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas
NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II
|
Kesari
|
|
A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer
NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I
|
Kesari
|
|
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
NCT ID : NCT03149003
Protocol Number : BBI-DSP7888-201G
Phase : II
|
Kesari
|